(Q44480340)

3 December 2017

Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas (English)

1 reference

3 December 2017

1 reference

Boniface J Lin

1

1 reference

3 December 2017

Huey-Peir Wu

2

1 reference

3 December 2017

H S Huang

3

1 reference

3 December 2017

Jyuhn-Huarng Juang

4

1 reference

3 December 2017

A Sison

5

1 reference

3 December 2017

Dato Khalid bin Abdul Kadir

6

1 reference

3 December 2017

Chung-Gu Cho

7

1 reference

3 December 2017

Witaya Sridama

8

1 reference

3 December 2017

Writing Group for the Asian Study of Acarbose with Sulfonylureas

9

1 reference

3 December 2017

language of work or name

1 reference

1 July 2003

1 reference

Journal of Diabetes and its Complications

3 December 2017

1 reference

3 December 2017

17

1 reference

3 December 2017

4

1 reference

3 December 2017

179-185

1 reference

Postprandial blood glucose. American Diabetes Association

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

The post-prandial state and cardiovascular disease: relevance to diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Diabetes mellitus: perspective from the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Hyperglycemia and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Asymptomatic hyperglycaemia and early atherosclerotic changes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

The U.K. Prospective Diabetes Study. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

Where is Malaysia in the midst of the Asian epidemic of diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900258-1

7 January 2021

10.1016/S1056-8727(02)00258-1

Identifiers

DOI

1 reference

3 December 2017

1 reference